Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil
Introduction: Cryptococcosis is a systemic fungal infection that affects humans and animals, mainly due to Cryptococcus neoformans and Cryptococcus gattii. Following the epidemic of acquired immunodeficiency syndrome (AIDS), fungal infections by C. neoformans have become more common among immunocomp...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2014-08-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/4446 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850148907420483584 |
|---|---|
| author | Olivia Cometti Favalessa Daphine Ariadne Jesus de Paula Valeria Dutra Luciano Nakazato Tomoko Tadano Marcia dos Santos Lazera Bodo Wanke Luciana Trilles Maria Walderez Szeszs Dayane Silva Rosane Christine Hahn |
| author_facet | Olivia Cometti Favalessa Daphine Ariadne Jesus de Paula Valeria Dutra Luciano Nakazato Tomoko Tadano Marcia dos Santos Lazera Bodo Wanke Luciana Trilles Maria Walderez Szeszs Dayane Silva Rosane Christine Hahn |
| author_sort | Olivia Cometti Favalessa |
| collection | DOAJ |
| description | Introduction: Cryptococcosis is a systemic fungal infection that affects humans and animals, mainly due to Cryptococcus neoformans and Cryptococcus gattii. Following the epidemic of acquired immunodeficiency syndrome (AIDS), fungal infections by C. neoformans have become more common among immunocompromised patients. Cryptococcus gattii has primarily been isolated as a primary pathogen in healthy hosts and occurs endemically in northern and northeastern Brazil. We to perform genotypic characterization and determine the in vitro susceptibility profile to antifungal drugs of the Cryptococcus species complex isolated from HIV-positive and HIV-negative patients attended at university hospitals in Cuiabá, MT, in the Midwestern region of Brazil.
Methodology: Micromorphological features, chemotyping with canavanine-glycine-bromothymol blue (CGB) agar and genotyping by URA5-RFLP were used to identify the species. The antifungal drugs tested were amphotericin B, fluconazole, flucytosine, itraconazole and voriconazole. Minimum inhibitory concentrations (MICs) were determined according to the CLSI methodology M27-A3.
Results: Analysis of samples yelded C. neoformans AFLP1/VNI (17/27, 63.0%) and C. gattii AFLP6/VGII (10/27, 37.0%). The MICs ranges for the antifungal drugs were: amphotericin B (0.5-1 mg/L), fluconazole (1-16 mg/L), flucytosine (1-16 mg/L), itraconazole (0.25-0.12 mg/L) and voriconazole (0.06-0.5 mg/L). Isolates of C. neoformans AFLP1/VNI were predominant in patients with HIV/AIDS, and C. gattii VGII in HIV-negative patients. The genotypes identified were susceptible to the antifungal drugs tested.
Conclusion: It is worth emphasizing that AFLP6/VGII is a predominant genotype affecting HIV-negative individuals in Cuiabá. These findings serve as a guide concerning the molecular epidemiology of C. neoformans and C. gattii in the State of Mato Grosso.
|
| format | Article |
| id | doaj-art-d6b15e67a8a74d19b7c2e0a9d0ba58ad |
| institution | OA Journals |
| issn | 1972-2680 |
| language | English |
| publishDate | 2014-08-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-d6b15e67a8a74d19b7c2e0a9d0ba58ad2025-08-20T02:27:06ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802014-08-0180810.3855/jidc.4446Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest BrazilOlivia Cometti Favalessa0Daphine Ariadne Jesus de Paula1Valeria Dutra2Luciano Nakazato3Tomoko Tadano4Marcia dos Santos Lazera5Bodo Wanke6Luciana Trilles7Maria Walderez Szeszs8Dayane Silva9Rosane Christine Hahn10Faculdade de Medicina, Universidade Federal de Mato Grosso, Cuiabá, MT, BrazilUniversidade Federal de Mato Grosso, Cuiabá, MT, BrazilUniversidade Federal de Mato Grosso, Cuiabá, MT, BrazilUniversidade Federal de Mato Grosso, Cuiabá, MT, BrazilUniversidade Federal de Mato Grosso, Cuiabá, MT, BrazilIPEC – Laboratório de Micologia - FIOCRUZ, Rio de Janeiro, RJ, BrazilIPEC – Laboratório de Micologia - FIOCRUZ, Rio de Janeiro, RJ, BrazilIPEC – Laboratório de Micologia - FIOCRUZ, Rio de Janeiro, RJ, BrazilIAL - Instituto Adolfo Lutz – Seção de Micologia São Paulo, SP, BrazilIAL - Instituto Adolfo Lutz – Seção de Micologia São Paulo, SP, BrazilFaculdade de Medicina, Universidade Federal de Mato Grosso, Cuiabá, MT, BrazilIntroduction: Cryptococcosis is a systemic fungal infection that affects humans and animals, mainly due to Cryptococcus neoformans and Cryptococcus gattii. Following the epidemic of acquired immunodeficiency syndrome (AIDS), fungal infections by C. neoformans have become more common among immunocompromised patients. Cryptococcus gattii has primarily been isolated as a primary pathogen in healthy hosts and occurs endemically in northern and northeastern Brazil. We to perform genotypic characterization and determine the in vitro susceptibility profile to antifungal drugs of the Cryptococcus species complex isolated from HIV-positive and HIV-negative patients attended at university hospitals in Cuiabá, MT, in the Midwestern region of Brazil. Methodology: Micromorphological features, chemotyping with canavanine-glycine-bromothymol blue (CGB) agar and genotyping by URA5-RFLP were used to identify the species. The antifungal drugs tested were amphotericin B, fluconazole, flucytosine, itraconazole and voriconazole. Minimum inhibitory concentrations (MICs) were determined according to the CLSI methodology M27-A3. Results: Analysis of samples yelded C. neoformans AFLP1/VNI (17/27, 63.0%) and C. gattii AFLP6/VGII (10/27, 37.0%). The MICs ranges for the antifungal drugs were: amphotericin B (0.5-1 mg/L), fluconazole (1-16 mg/L), flucytosine (1-16 mg/L), itraconazole (0.25-0.12 mg/L) and voriconazole (0.06-0.5 mg/L). Isolates of C. neoformans AFLP1/VNI were predominant in patients with HIV/AIDS, and C. gattii VGII in HIV-negative patients. The genotypes identified were susceptible to the antifungal drugs tested. Conclusion: It is worth emphasizing that AFLP6/VGII is a predominant genotype affecting HIV-negative individuals in Cuiabá. These findings serve as a guide concerning the molecular epidemiology of C. neoformans and C. gattii in the State of Mato Grosso. https://jidc.org/index.php/journal/article/view/4446CryptococosisCryptococcus complexantifungal drugs |
| spellingShingle | Olivia Cometti Favalessa Daphine Ariadne Jesus de Paula Valeria Dutra Luciano Nakazato Tomoko Tadano Marcia dos Santos Lazera Bodo Wanke Luciana Trilles Maria Walderez Szeszs Dayane Silva Rosane Christine Hahn Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil Journal of Infection in Developing Countries Cryptococosis Cryptococcus complex antifungal drugs |
| title | Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil |
| title_full | Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil |
| title_fullStr | Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil |
| title_full_unstemmed | Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil |
| title_short | Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil |
| title_sort | molecular typing and in vitro antifungal susceptibility of cryptococcus spp from patients in midwest brazil |
| topic | Cryptococosis Cryptococcus complex antifungal drugs |
| url | https://jidc.org/index.php/journal/article/view/4446 |
| work_keys_str_mv | AT oliviacomettifavalessa moleculartypingandinvitroantifungalsusceptibilityofcryptococcussppfrompatientsinmidwestbrazil AT daphineariadnejesusdepaula moleculartypingandinvitroantifungalsusceptibilityofcryptococcussppfrompatientsinmidwestbrazil AT valeriadutra moleculartypingandinvitroantifungalsusceptibilityofcryptococcussppfrompatientsinmidwestbrazil AT lucianonakazato moleculartypingandinvitroantifungalsusceptibilityofcryptococcussppfrompatientsinmidwestbrazil AT tomokotadano moleculartypingandinvitroantifungalsusceptibilityofcryptococcussppfrompatientsinmidwestbrazil AT marciadossantoslazera moleculartypingandinvitroantifungalsusceptibilityofcryptococcussppfrompatientsinmidwestbrazil AT bodowanke moleculartypingandinvitroantifungalsusceptibilityofcryptococcussppfrompatientsinmidwestbrazil AT lucianatrilles moleculartypingandinvitroantifungalsusceptibilityofcryptococcussppfrompatientsinmidwestbrazil AT mariawalderezszeszs moleculartypingandinvitroantifungalsusceptibilityofcryptococcussppfrompatientsinmidwestbrazil AT dayanesilva moleculartypingandinvitroantifungalsusceptibilityofcryptococcussppfrompatientsinmidwestbrazil AT rosanechristinehahn moleculartypingandinvitroantifungalsusceptibilityofcryptococcussppfrompatientsinmidwestbrazil |